Drug General Information (ID: DDI8T6L1NV)
Drug Name			Canakinumab		Drug Info		Rilonacept		Drug Info
Drug Type		Monoclonal antibody				Protein/peptide
Therapeutic Class		Interleukin Inhibitors				Interleukin Inhibitors

Mechanism of Canakinumab-Rilonacept Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Canakinumab				Rilonacept
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Canakinumab and Rilonacept

Recommended Action
Management		Simultaneous use of agents that block interleukin-1 or its receptors is not recommended.

References
1	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
2	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.